Table 2 Clinical outcomes
| Â | Pediatric cohort | p-value | Adult cohort | p-value | ||
|---|---|---|---|---|---|---|
AKI group (n = 41) | Non-AKI group (n = 113) | AKI group (n = 218) | Non-AKI group (n = 368) | |||
Follow-up time (years) | 11.68 ± 1.23 | 11.42 ± 1.77 | 0.534 | 11.17 ± 2.20 | 11.58 ± 1.30 | 0.254 |
DGF, n (%) | 14 (34.1) | 29 (16.8) | 0.021 | 84 (38.5) | 64 (17.4) |  < 0.01 |
Acute rejection first year | 7 (17.1) | 16 (14.2) | 0.654 | 29 (13.3) | 47 (12.8) | 0.853 |
SCr (µmol/L) |  |  |  |  |  |  |
 1 week | 326.70 (100.35–609.85) | 175.40 (109.20–336.15) | 0.264 | 246.70 (153.05–614.03) | 172.95 (116.75–369.95) |  < 0.01 |
 1 month | 103.80 (83.70–140.05) | 108.10 (86.40–136.35) | 0.765 | 141.20 (115.00–182.05) | 128.40 (102.80–161.60) | 0.003 |
 6 months | 103.20 (76.35–127.40) | 93.20 (78.30–108.00) | 0.066 | 125.30 (102.30–146.85) | 113.90 (97.00–138.70) | 0.017 |
 12 months | 93.00 (79.00–109.75) | 85.10 (71.05–104.10) | 0.153 | 120.00 (100.55–139.00) | 114.00 (95.00–134.48) | 0.075 |
eGFR (mL/min*1.73Â m2) | Â | Â | Â | Â | Â | Â |
 1 week | 16.49 (9.79–68.37) | 38.37 (19.35–64.66) | 0.308 | 24.38 (8.68–45.24) | 38.48 (15.55–62.39) |  < 0.01 |
 1 month | 70.92 (48.34–94.53) | 68.87 (54.19–87.80) | 0.748 | 48.35 (36.34–63.94) | 55.72 (41.84–72.47) | 0.005 |
 6 months | 73.15 (56.91–97.03) | 83.15 (70.13–99.17) | 0.148 | 57.32 (46.65–74.60) | 63.87 (50.42–78.65) | 0.025 |
 12 months | 86.62 (71.00–102.64) | 87.54 (77.9–106.69) | 0.226 | 63.21 (48.34–78.14) | 65.05 (53.76–78.55) | 0.142 |
1-year clinical outcome | Â | Â | Â | Â | Â | Â |
 Graft loss incident, n (%) | 1 (2.4) | 1 (0.9) | 0.452 | 1 (0.5) | 6 (1.6) | 0.207 |
 Death-censored graft survival rate, (%) | 97.4 | 99.1 | 0.472 | 99.5 | 98.3 | 0.217 |
 Patient death incident, (%) | 0 | 3 (2.7) | 0.565 | 5 (2.3) | 6 (1.6) | 0.568 |
 Patient survival, (%) | 100 | 97.3 | 0.295 | 97.7 | 98.3 | 0.544 |